Your browser doesn't support javascript.
loading
The use of naltrexone in the treatment of chronic pain: a systematic review.
Rassi-Mariani, Victor; Barreto, Eduardo Silva Reis; Antunes, César Romero; Alencar, Vinicius Borges; Falcão Lins-Kusterer, Liliane Elze; Azi, Liana Maria Torres de Araujo; Kraychete, Durval Campos.
Afiliação
  • Rassi-Mariani V; Federal University of Bahia, Salvador, Bahia, Brazil.
  • Barreto ESR; Federal University of Bahia, Salvador, Bahia, Brazil.
  • Antunes CR; Federal University of Bahia, Salvador, Bahia, Brazil.
  • Alencar VB; Federal University of Bahia, Salvador, Bahia, Brazil.
  • Falcão Lins-Kusterer LE; Federal University of Bahia, Salvador, Bahia, Brazil.
  • Azi LMTA; Federal University of Bahia, Salvador, Bahia, Brazil.
  • Kraychete DC; Federal University of Bahia, Salvador, Bahia, Brazil.
Pain Manag ; 14(8): 453-463, 2024.
Article em En | MEDLINE | ID: mdl-39301937
ABSTRACT
This study aims to assess the efficacy of low-dose naltrexone (LDN) in treating chronic pain. We conducted a systematic review using the PICO strategy (P) Patients with chronic pain, (I) Use of oral naltrexone, (C) Placebo or active drug and (O) Pain relief and quality of life. We included articles from PubMed, Scopus, Cochrane CENTRAL and EMBASE databases. Seven randomized clinical trials involving 406 patients were analyzed. The doses ranging from 2 to 4.5 mg once daily across all studies. Various chronic pain conditions were evaluated. The results suggest that low-dose naltrexone is not effective in managing chronic pain and improving the quality of life in patients with diverse chronic pain conditions. However, further research with larger sample sizes and standardized methodologies is necessary.
This study looks at how well low-dose naltrexone (LDN) works for treating long-lasting pain. We reviewed research where patients with chronic pain were given either LDN or a placebo (a fake treatment). We found eight studies that included a total of 421 patients. The LDN doses used ranged from very small amounts 2­4.5 mg, taken once a day. These studies looked at different types of chronic pain. Our results suggest that LDN cannot help to reduce pain and improve the quality of life for people with chronic pain. However, more research with larger groups of people and consistent methods is needed to confirm these findings.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor Crônica / Naltrexona / Antagonistas de Entorpecentes Limite: Humans Idioma: En Revista: Pain Manag Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor Crônica / Naltrexona / Antagonistas de Entorpecentes Limite: Humans Idioma: En Revista: Pain Manag Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Reino Unido